Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 4, 2004, Pages 355-363

  Fullerton, N E ^a,b   Boyd, M ^a   Mairs, R J ^a   Keith, W N ^a   Alderwish, O ^a,b   Brown, M M ^a,b   Livingstone, A ^a   Kirk, D ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

131I MIBG; Bystander effect; Gene therapy; Targeted radiotherapy; Telomerase

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; NORADRENALIN TRANSPORTER; TELOMERASE; (3 IODOBENZYL)GUANIDINE; COTRANSPORTER; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; SLC6A2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BEAM THERAPY; BYSTANDER EFFECT; CANCER CELL CULTURE; CYTOTOXICITY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MORBIDITY; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; TRANSGENE; TUMOR SPHEROID; ADENOCARCINOMA; CELL CULTURE; DRUG SCREENING; GENETICS; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR;

3-IODOBENZYLGUANIDINE; ADENOCARCINOMA; BYSTANDER EFFECT; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SYMPORTERS; TELOMERASE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 16644383142     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500760     Document Type: Article

References (42)

1. Weir HK et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276-1299.
2. Duchesne GM. Radiation for prostate cancer. Lancet Oncol 2001; 2: 73-81.
3. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233-241.
4. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31: 1257-1280.
5. Gaze MN, Wheldon TE. Radiolabelled mIBG in the treatment of neuroblastoma. Eur J Cancer 1996; 32A: 93-96.
6. 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997; 17: 1823-1831.
7. 131I]MIBG). Clin Endocrinol (Oxf) 2001; 55: 47-60.
8. 131I]metaiodobenzylguanidine. Gene Therapy 1999; 6: 1147-1152.
9. 131I]metaiodobenzylguanidine. J Gene Med 2001; 3: 165-172.
10. Mairs RJ, Cunningham SH, Boyd M, Carlin S. Applications of gene transfer to targeted radiotherapy. Cur Pharm Des 2000; 6: 1419-1432.
11. 131I]MIBG and clonogenic cell kill. Oncogene 2001; 20: 7804-7808.
12. Plumb JA et al. Telomerase specific suicide gene therapy vectors expressing bacterial nitroreductase sensitise human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797-7803.
13. Sommerfeld HJ et al. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-222.
14. Lin Y et al. Telomerase activity in primary prostate cancer. J Urol 1997; 157: 1161-1165.
15. Shay JW, Bacchetti. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
16. Kim NW, Hruszkewycz AM. Telomerase activity modulation in the prevention of prostate cancer. Urology 2001; 57 (Suppl. 4A): 148-153.
17. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001; 166: 666-673.
18. Orlando C, Gelmini S. Telomerase in endocrine and endocrine-dependent tumours. J Steroid Biochem Mol Biol 2001; 78: 201-214.
19. 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 6: 387-394.
20. Ballangrud AM et al. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Canc Res (Suppl) 1999; 5: 3171s-3176s.
21. Hedlund TE, Duke RC, Miller GJ. Three-dimensional spheroid cultures of human prostate cancer cell lines. Prostate 1999; 41: 154-165.
22. Boyd M et al. Transfectant mosaic spheroids: A new model for evaluation of bystander effects in experimental gene therapy. J Gene Med 2002; 4: 1-10.
23. Cunningham S et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol 2000; 35: 708-711.
24. Steiner MS, Gingrich JR. Gene therapy for prostate cancer: Where are we now? J Urol 2000; 164: 1121-1136.
25. Maitland NJ. Targeting therapeutic gene expression to human prostate cancers. Curr Opin Mol Ther 2000; 2: 389-399.
26. Koeneman KS, Hsieh J-T. The prospect of gene therapy for prostate cancer: Update on theory and status. Curr Opin Urol 2001; 11: 489-494.
27. McKenzie KE, Umbricht CE, Saraswati S. Applications of telomerase research in the fight against cancer. Mol Med Today 1999; 5: 114-122.
28. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Ann Rev Med 2000; 51: 65-79.
29. Keith WN, Evans TRJ, Glasspool RM. Telomerase and cancer: Time to move from a promising target to a clinical reality. J Pathol 2001; 195: 404-414.
30. Boyd M et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation mediated bystander effects. J Gene Med 2004; 6: 937-947.
31. Spitzweg C et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-2141.
32. Lee SE et al. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res 2000; 20: 417-422.
33. Djordjevic B. Bystander effects: A concept in need of clarification. BioEssays 2000; 22: 286-290.
34. Belyakov OV et al. Direct evidence for a bystander effect of ionising radiation in primary human fibroblasts. Br J Cancer 2001; 84: 674-679.
35. Hall EJ. The bystander effect. Health Phys 2003; 85: 31-35.
36. 90Y. Radiother Oncol 1991; 21: 91-99.
37. 131I]meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992; 66: 1048-1052.
38. Cunningham SH et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77: 2061-2068.
39. Allen BJ. Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 1999; 43: 480-486.
40. Zalutsky MR, G. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433-1455.
41. Imam SK. Advancements in cancer therapy with alpha-emitters: A review. Int J Radiat Oncol Biol Phys 2001; 51: 271-278.
42. Jurcic JG et al. Targeted α particle immunotherapy for myeloid leukaemia. Blood 2002; 100: 1233-1239.